AAV Platform Process Accelerating Production from Gene to Clinic
Summary: AAV, or adeno-associated virus, is considered the gold standard for in vivo gene delivery transfer and has become the leading viral vector choice for gene therapies today. As one of the field’s most effective delivery tools, AAV has shown strong clinical success and recent improvements in related technology and system approaches have made AAV production an efficient means to meet clinical and commercial requirements. In this on-demand webinar, hear our product development expert discuss Catalent’s UpTempo Virtuoso AAV platform process, a scalable, CGMP-ready platform process that can significantly reduce the time from gene to clinic.